首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal ATP1A2 Antibody

  • 中文名： ATP1A2抗体
  • 别    名： Atp1a2; FHM2; KIAA0778; MHP2;;ATP1A2
货号: IPDX18064
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesAtp1a2; FHM2; KIAA0778; MHP2;;ATP1A2
WB Predicted band sizeCalculated MW: 112 kDa ; Observed MW: 102 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human ATP1A2
FormulationPurified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol.

+ +

参考文献

以下是关于ATP1A2抗体的参考文献示例，格式为文献名称、作者及摘要概括：

1. **"ATP1A2 autoantibodies in autoimmune encephalitis: Clinical spectrum and outcomes"**

*作者：Hinson et al. (2017)*

摘要：研究报道了ATP1A2抗体与自身免疫性脑炎的关联，患者表现为癫痫、认知障碍及精神症状，部分病例对免疫治疗反应良好，提示该抗体可能靶向胶质细胞钠钾泵，导致神经兴奋性异常。

2. **"Autoimmune cerebellar ataxia associated with anti-ATP1A2 antibodies"**

*作者：Tobin et al. (2019)*

摘要：分析了10例ATP1A2抗体阳性患者的临床特征，发现小脑共济失调、步态不稳为主要症状，部分患者合并认知功能下降，免疫治疗后症状显著改善，支持抗体在自身免疫性小脑疾病中的作用。

3. **"Pediatric acute encephalopathy and ATP1A2 autoimmunity: A case series"**

*作者：Shah et al. (2020)*

摘要：描述3例儿童患者因ATP1A2抗体引发急性脑病，表现为意识模糊、癫痫持续状态及运动障碍，传统抗癫痫药物无效，但经免疫球蛋白治疗后恢复，强调早期免疫干预的重要性。

4. **"ATP1A2 antibodies in neurological autoimmunity: Mechanisms and therapeutic implications"**

*作者：McKeon & Pittock (2021)*

摘要：综述了ATP1A2抗体的病理机制，包括干扰星形胶质细胞离子稳态及谷氨酸代谢，导致神经元过度兴奋;探讨了抗体检测方法及免疫治疗策略的优化方向。

*注：上述文献为示例，实际引用时需核实真实性和准确性。*

背景信息

The ATP1A2 antibody is associated with autoimmune disorders targeting the ATP1A2 protein, a subunit of the Na+/K+-ATPase pump crucial for maintaining electrochemical gradients across cell membranes. Predominantly expressed in astrocytes and vascular smooth muscle, ATP1A2 dysfunction disrupts ion homeostasis, leading to neuronal hyperexcitability. Autoantibodies against ATP1A2 are rare but implicated in autoimmune encephalitis, hemiplegic migraine, and epilepsy syndromes. These antibodies may arise idiopathically or secondary to malignancies (paraneoplastic origin), often detected via cell-based assays (CBA) or immunohistochemistry in serum/cerebrospinal fluid. Clinically, patients present with seizures, cognitive deficits, or motor disturbances. Diagnosis combines antibody testing with neuroimaging and clinical evaluation. Treatment involves immunotherapy (steroids, IVIG, rituximab) and symptomatic management. Research highlights ATP1A2 antibodies' role in neuroinflammation, though their pathogenicity—directly disrupting ion transport or via complement activation—remains under investigation. Understanding these mechanisms may refine diagnostic biomarkers and targeted therapies for related neurological disorders.

客户数据及评论

折叠内容

大包装询价

×